I’m not a medic, but in the NHP the treatment related adverse effects begin somewhere between 12 mg/kg and 30 mg/kg. So I’d assume the Phase 1 human trial (healthy volunteers) might start at 3 mg/kg and go to 9 and 12 if they have 3 cohorts? Or maybe they’ll just have 1 cohort and use the next phase as a dose range-finder? A brief skim of the results shows that PYC003 concentration increases from the dose of 3 mg/kg to about 500 mg/g in the target tissue. That’s an increase in concentration of about 165 times. So no wonder the 30 mg/kg dose produced some TRAE.
All in all I’m excited about this. This thing is a sleeping giant IMO.
PYC Price at posting:
$2.00 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)